Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

8.025 +0.315 (+4.09%)
Delayed Quote Updated: 10:21 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
News headline image
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
From Verastem Oncology
Via Business Wire
News headline image
Analyst Ratings for Verastem ↗
 
Via Benzinga
News headline image
Truist Securities Maintains Buy Rating for Verastem: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged ↗
The company is testing a treatment for a form of ovarian cancer. 
Via Investor's Business Daily
News headline image
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗
 
Via Benzinga
News headline image
3 Penny Stocks That Can Triple Your Money in the Next 12 Months ↗
Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing. 
Via InvestorPlace
News headline image
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal ↗
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet... 
Via Talk Markets
News headline image
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket ↗
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use... 
Via Benzinga
News headline image
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
News headline image
Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results ↗
U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500,... 
Via Benzinga
News headline image
Verastem's Ovarian Cancer Drug Showing Promise, Analyst Upgrades Stock ↗
Mizuho Securities has upgraded Verastem Inc (NASDAQ: VSTM) from Neutral to Buy with a price target of $36, up from $24, to  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1%... 
Via Benzinga
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
Via AB Newswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.